Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
3.250
-0.220 (-6.34%)
Dec 5, 2025, 4:00 PM EST - Market closed
Serina Therapeutics Revenue
Serina Therapeutics had revenue of $116.00K in the twelve months ending September 30, 2025, down -96.33% year-over-year. In the year 2024, Serina Therapeutics had annual revenue of $56.00K, down -98.22%.
Revenue (ttm)
$116.00K
Revenue Growth
-96.33%
P/S Ratio
274.66
Revenue / Employee
$8,923
Employees
13
Market Cap
34.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.00K | -3.10M | -98.22% |
| Dec 31, 2023 | 3.15M | 2.56M | 433.05% |
| Dec 31, 2022 | 591.50K | 447.50K | 310.76% |
| Dec 31, 2021 | 144.00K | -217.00K | -60.11% |
| Dec 31, 2020 | 361.00K | -1.37M | -79.11% |
| Dec 31, 2019 | 1.73M | 332.00K | 23.78% |
| Dec 31, 2018 | 1.40M | -8.00K | -0.57% |
| Dec 31, 2017 | 1.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SER News
- 23 days ago - Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 4 weeks ago - Serina Therapeutics Provides Regulatory Update on SER-252 Program - GlobeNewsWire
- 2 months ago - Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors - GlobeNewsWire
- 2 months ago - Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire
- 3 months ago - Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire
- 3 months ago - Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway - GlobeNewsWire
- 4 months ago - Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire